Alliancebernstein L.P. Arrowhead Pharmaceuticals, Inc. Transaction History

Alliancebernstein L.P.

$280 Billion
Q4 2024

A detailed history of Alliancebernstein L.P. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 265,482 shares of ARWR stock, worth $4.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

265,482

Previous 265,923 0.17%

Holding current value

$4.04 Million

Previous $5.15 Million 3.05%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	SELL	$17.7 - $26.34 $7,805 - $11,615	-441 Reduced 0.17%	265,482 $4.99 Million
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $177,260 - $270,468	-9,156 Reduced 3.33%	265,923 $5.15 Million
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $682,912 - $881,822	31,226 Added 12.81%	275,079 $7.15 Million
Q1 2024 May 14, 2024	BUY	$27.21 - $39.48 $493,262 - $715,693	18,128 Added 8.03%	243,853 $6.97 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $22,705 - $33,233	-1,071 Reduced 0.47%	225,725 $6.91 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $119,183 - $164,127	-4,549 Reduced 1.97%	226,796 $6.09 Million
Q2 2023 Aug 15, 2023	SELL	$25.16 - $41.38 $1.81 Million - $2.97 Million	-71,841 Reduced 23.7%	231,345 $8.25 Million
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $54 Million - $87.9 Million	-2,281,507 Reduced 88.27%	303,186 $7.7 Million
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $3.29 Million - $4.77 Million	117,633 Added 4.77%	2,584,693 $105 Million
Q3 2022 Nov 15, 2022	SELL	$29.63 - $48.31 $9.81 Million - $16 Million	-331,074 Reduced 11.83%	2,467,060 $81.5 Million
Q2 2022 Aug 15, 2022	BUY	$27.79 - $50.61 $1.16 Million - $2.12 Million	41,803 Added 1.52%	2,798,134 $98.5 Million
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $11.6 Million - $20.4 Million	291,820 Added 11.84%	2,756,331 $127 Million
Q4 2021 Feb 14, 2022	BUY	$58.09 - $82.51 $86.8 Million - $123 Million	1,494,218 Added 154.0%	2,464,511 $163 Million
Q3 2021 Nov 10, 2021	SELL	$58.38 - $84.96 $8.56 Million - $12.5 Million	-146,587 Reduced 13.12%	970,293 $60.6 Million
Q2 2021 Jul 30, 2021	BUY	$62.15 - $90.32 $3.16 Million - $4.6 Million	50,883 Added 4.77%	1,116,880 $92.5 Million
Q1 2021 May 06, 2021	BUY	$61.35 - $90.47 $46.6 Million - $68.8 Million	760,005 Added 248.37%	1,065,997 $70.7 Million
Q4 2020 Feb 08, 2021	SELL	$43.82 - $85.37 $550,379 - $1.07 Million	-12,560 Reduced 3.94%	305,992 $23.5 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $1.22 Million - $1.88 Million	-36,718 Reduced 10.34%	318,552 $13.7 Million
Q2 2020 Aug 13, 2020	BUY	$26.12 - $43.27 $834,795 - $1.38 Million	31,960 Added 9.89%	355,270 $15.3 Million
Q1 2020 May 14, 2020	SELL	$20.56 - $63.12 $140,013 - $429,847	-6,810 Reduced 2.06%	323,310 $9.3 Million
Q4 2019 Feb 18, 2020	BUY	$28.14 - $73.01 $2.36 Million - $6.12 Million	83,850 Added 34.05%	330,120 $20.9 Million
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $527,826 - $700,686	-20,100 Reduced 7.55%	246,270 $6.94 Million
Q2 2019 Aug 14, 2019	BUY	$17.43 - $28.82 $2.7 Million - $4.47 Million	154,998 Added 139.17%	266,370 $7.06 Million
Q1 2019 May 14, 2019	SELL	$12.05 - $20.18 $220,852 - $369,859	-18,328 Reduced 14.13%	111,372 $2.04 Million
Q3 2018 Nov 08, 2018	BUY	$14.0 - $20.3 $373,800 - $542,010	26,700 Added 25.92%	129,700 $2.49 Million
Q2 2018 Aug 13, 2018	BUY	$6.37 - $14.02 $656,110 - $1.44 Million	103,000 New	103,000 $1.4 Million

Others Institutions Holding ARWR

# of Institutions

305

Shares Held

95.9M

Call Options Held

523K

Put Options Held

493K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.61B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Arrowhead Pharmaceuticals, Inc. Transaction History